THE ROLE OF HYPERPROLACTINEMIA IN REPRODUCTIVE AND METABOLIC ENDOCRINE DISORDERS
Keywords:
hyperprolactinemia, prolactin, prolactinoma, dopamine, infertility, hypogonadism, pituitary gland, endocrine disorder.Abstract
Hyperprolactinemia is an endocrine disorder characterized by persistently elevated serum prolactin concentrations and may result from physiological conditions, medications, hypothalamic-pituitary disease, or systemic disorders. The condition has important effects on reproductive, gonadal, metabolic, and neuroendocrine function. The aim of this study was to analyze the major pathophysiological mechanisms, clinical manifestations, diagnostic principles, and treatment strategies associated with hyperprolactinemia. A literature-based analytical approach was used to evaluate prolactin synthesis, dopamine-mediated inhibition, gonadotropin-releasing hormone suppression, pituitary adenomas, medication-induced hyperprolactinemia, and associated reproductive dysfunction. The analysis indicates that excessive prolactin inhibits hypothalamic GnRH secretion, leading to reduced luteinizing hormone and follicle-stimulating hormone release and subsequent hypogonadism. In women, this may cause menstrual disturbances, infertility, and galactorrhea, whereas men may develop reduced libido, erectile dysfunction, infertility, and decreased testosterone levels. Prolactinomas represent an important pathological cause, while dopamine antagonist medications are among the most common pharmacological causes. Accurate diagnosis requires confirmation of persistent prolactin elevation, exclusion of physiological and secondary causes, evaluation of thyroid and renal function, and pituitary imaging when indicated. Dopamine agonists remain the principal treatment in most symptomatic prolactinomas and can normalize prolactin secretion and reduce tumor size. Hyperprolactinemia should therefore be considered an important endocrine disorder with both reproductive and systemic consequences.
References
1.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(2):273–288.
2.Скворцова, Л. А., Махмудов, Д. Э., Усманов, Д. Р., Адылходжаев, А. А., & Хегай, Л. Н. (2019). АСПЕКТЫ СПОРТИВНОЙ АДАПТОЛОГИИ ПРИ ИЗУЧЕНИИ ВИТАМИНА D 25 (OH) D У ФУТБОЛИСТОВ. In От фундаментальных знаний к тонкому владению скальпелем (pp. 51-54).
3.Хегай, Л. Н., Скворцова, Л. А., Махмудов, Д. Э., Усманов, Д. Р., Муслимов, О. Я., & Адылходжаев, А. А. (2019). СОДЕРЖАНИЕ 25-OH-ВИТАМИНА D У ФУТБОЛИСТОВ В УСЛОВИЯХ СОЛНЕЧНОЙ РАДИАЦИИ УЗБЕКИСТАНА. In Actual Questions and Innovations in Science 2 (pp. 160-161).
4.Mavlyanov, I., Parpiev, S., Sadikov, A., Kurganov, S., & Makhmudov, D. (2020). Relative features of the PPARA (Rs4253778), PPARGC1A (Rs8192678) and PPARG2 (Rs1801282) polymorphisms genes in athletes engaged in cyclic types of sports. European Journal of Molecular and Clinical Medicine, 7(2), 1860-1869.
5.Пирназаров, М. М., Садиков, А. А., Махмудов, Д. Э., & Хегай, Л. Н. (2021). Магнитно-резонансная томографическая визуализация повреждений коленных суставов. Re-health journal, (1 (9)), 152-159.
6.Махмудов, Д. Э., & Саитов, Т. А. (2023). Анализ персонализированного питания высококвалифицированных спортсменов управленческих видов спорта. Klinik va profilaktik tibbiyot jurnali, (3), 79.
7.Махмудов, Д. Э., & Саитов, Т. А. (2023). Анализ персонализированного питания высококвалифицированных спортсменов управленческих видов спорта. Klinik va profilaktik tibbiyot jurnali, (3), 79.
8.Таралева, Т. А., Махмудов, Д. Э., Атабаева, С. М., & Сагитов, Д. М. (2026). ВАРИАБЕЛЬНОСТЬ СЕРДЕЧНОГО РИТМА В ЦИКЛИЧЕСКИХ ВИДАХ СПОРТА: СОВРЕМЕННЫЕ ПОДХОДЫ К ОЦЕНКЕ ФУНКЦИОНАЛЬНОГО СОСТОЯНИЯ СПОРТСМЕНОВ. South Aral Region Medical Journal, 2(Maxsus son-2), 587-593.
9.Махмудов, Д., Абдуллаева, Х., Таралева, Т., Аблялимов, Р., & Парпиев, С. (2025). АНАЛИЗ ФУНКЦИОНАЛЬНЫХ ПОКАЗАТЕЛЕЙ ФУТБОЛИСТОВ НА ЭТАПЕ ОТБОРА К СОРЕВНОВАНИЯМ. Медицина и спорт, (3), 162-162.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal